SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...

Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

Hengrui Pharma partners with GSK to develop 12 innovative medicines, enhancing COPD treatment and expanding global growth ...

The deal comes as GSK, led by chief exec Emma Walmsley (pictured) focuses on growing its pipeline to offset declining ...

AbbVie, Gilead Sciences and GSK marked World Hepatitis Day on Monday, outlining the need to tackle the stigma and ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

London: GSK plc has announced it has entered into agreements with Hengrui Pharma (600276.SH; 01276.HK) to develop up to 12 ...

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...

GSK is paying $500M upfront for rights to a series of Hengrui drugs, the latest case of a pharma company looking to a Chinese ...